Corcept Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call
(firmenpresse) - MENLO PARK, CA -- (Marketwired) -- 11/04/13 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter 2013 financial results on November 7, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
To participate, dial 1-888-771-4371 from the United States or +1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 35967600.
A replay will be available through November 21, 2013 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode is 35967600.
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. Korlym, a first generation competitive GR-II antagonist, is the company's first FDA-approved medication. The company has a phase 3 trial underway for mifepristone for treatment of the psychotic features of psychotic depression and a portfolio of selective GR-II antagonists that competitively block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR-II antagonists, including mifepristone, in the treatment of a wide variety of metabolic, psychiatric and other disorders. It also holds composition of matter patents for its selective GR-II antagonists.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.11.2013 - 16:00 Uhr
Sprache: Deutsch
News-ID 1279223
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MENLO PARK, CA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 138 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Corcept Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call
"
steht unter der journalistisch-redaktionellen Verantwortung von
Corcept Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
